The future of dyslipidemia therapy
Authors:
V. Chaloupka
Authors‘ workplace:
Interní kardiologická klinika FN Brno-Bohunice
Published in:
Kardiol Rev Int Med 2009, 11(4): 191-196
Category:
Notice
Overview
Currently, statins represent the key drug group for management of dyslipidemias. They importantly reduce concentration of cholesterol in low‑density lipoproteins. A number of patients do not achieve target values for the total as well as LDL‑cholesterol. Most frequently, this is because physicians prescribe too low doses of statins in monotherapy, and do not increase these doses, as well as because of the absence of combination therapy that represents the future of dyslipidemia treatment. The statin/ezetimibe or statin/fibrate combinations are common at present; the statin/fibrate/ezetimibe combination might also be used. The well‑tested niacin is soon to be available on the market (niacin/laropiprant), thus importantly broadening the combination therapy options.
Key words:
dyslipidemia – statins – fibrates – ezetimibe – niacin – combination therapy
Sources
1. Ballantyne C. Evolving concepts and a new approach for management of hyperlipidemia. Eur Hear J 2002; 4: J1–J3.
2. Joint Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Joint national Committee on detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA 1977; 237: 256–261.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Report of the National Cholesterol Education program Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148: 36–69.
4. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
5. Sacks FM, Pfeffer MA, Moye L et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.
6. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
7. The Long‑term Intervention with Pravastatin in Ischemic Disease (LIPID) Study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.
8. Downs JR, Clearfield M, Weis S et al for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–1622.
9. Kastelein J, van Dam MJ. A new role for combination therapy in lipid management. Br J Cardiol 2001; 8: 639–653.
10. EuroAspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EuroAspire II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.
11. Lipid‑altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10mg in high‑risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy. Int J Clin Pract 2009; 63: 547–559.
12. Schectman G, Hiatt J. Dose‑response characteristics of cholesterol‑lowering therapies: Implication for treatment. Ann Intern Med 1996; 125: 990–1000.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high‑risk individuals: a randomized placebo‑controlled trial. Lancet 2002; 360: 7–22.
14. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo‑Scandinavian Cardiac Outcomes Trial‑Lipid Lowering Arm (ASCOT‑LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158.
15. Keating GM, Ormrod D. Micronised fenofibrate: an update review of its clinical efficacy in the management of dyslipidemia. Drugs 2002; 62: 1909–1944.
16. Rubins HB, Robins SJ, Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high‑density lipoprotein cholesterol. Veterans Affairs High‑Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418.
17. De Faire U, Ericsson CG, Grip L et al. Secondary preventive potential of lipid‑lowering drugs. The Bezafibrate Coronary Atherosclerosis Interventional Trial (BECAIT). Eur Heart J 1996; 17: 37–42.
18. The FIELD Study Investigators. Effects of long term fenofibrate therapy on cardiovascular events in 9 795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 26: 1849–1861.
19. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on The need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687–1697.
20. Third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Final Report. Circulation 2002; 106: 3143–3421.
21. Maccubbin D, Bays HE, Olsson AG et al. Lipid‑ modifying efficacy and tolerability of extended‑release niacin/laropiprant in patient with primary hypercholesterolemia or mixed dyslipidemia. Clin Pract 2008; 62: 1959–1970.
22. Darkes MJM, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs 2003; 3: 67–76.
23. van Heek M, Farley C, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000; 129: 1748–1754.
24. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943–1948.
25. Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23: 1209–1230.
26. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 2001; Suppl. E: E 11–16.
27. Athyros VG, Papageorgiou AA, Konstantidou HA et al. Safety and efficacy of long‑term statin‑fibrate combinations in patients with refractory familiar combined hyperlipidemia. Am J Cardiol 1997; 80: 608–613.
28. Jones PH, Davison MH. Reporting rates of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120–122.
29. Carlson LA, Resenheimer G. Reduction of mortality in the Stockholm ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 233: 405–418.
30. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation 2003; 107: 2409–2415.
31. Davidson M, Mc Garry T, Bettis R et al. Ezetimibe coadministered with Simvastatin in patiens with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125–2134.
32. Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897–905.
33. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.
34. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low‑ density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998; 19: A24–30.
35. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004; 350: 1495–1504.
36. Fruchart JC, Sacks FM, Hermans MP et al. The residual risk initiave: a call to action to reduce residual vascular risk in dyslipideamic patient. Diabetes Vasc Dis Res 2008; 5: 319–335.
37. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C‑reaktive protein. N Engl J Med 2008; 359: 2195–2207.
38. Olsson AG, Schwartz GG, Szarek M et al. High‑density lipoprotein, but not low‑density lipoprotein cholesterol levels influence short‑term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26: 890–896.
39. Barter P, Kastelein J, Nunn A et al. High density lipoproteins (HDLs) and atherosclerosis; the unanswered question. Atherosclerosis 2003; 168: 195–211.
40. Tailor AJ, Sullengerger LE, Lee HJ et al. Arterial Biology for the investigation of the Treatment Effect of Reducing Cholesterol (ARBITER) 2: a double‑blind, placebo – controlled study of extended‑release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512–3517.
41. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. Eng J Med 2001; 345: 1583–1592.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
![Issue 4](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/5259eddb2fa5e90d6a56c0194a28102e.jpeg)
2009 Issue 4
Most read in this issue
- Pleural effusion – aetiology and diagnostics
- Pulmonary embolism
- Congenital heart defects with pulmonary hypertension
- Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease